These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 23243043

  • 1. Clinical outcome with low-dose valacyclovir in high-risk renal transplant recipients: a 10-year experience.
    Sund F, Tufveson G, Döhler B, Opelz G, Eriksson BM.
    Nephrol Dial Transplant; 2013 Mar; 28(3):758-65. PubMed ID: 23243043
    [Abstract] [Full Text] [Related]

  • 2. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.
    Lowance D, Neumayer HH, Legendre CM, Squifflet JP, Kovarik J, Brennan PJ, Norman D, Mendez R, Keating MR, Coggon GL, Crisp A, Lee IC.
    N Engl J Med; 1999 May 13; 340(19):1462-70. PubMed ID: 10320384
    [Abstract] [Full Text] [Related]

  • 3. CMV disease in CMV-mismatched renal transplant recipients with prophylactic low dose valaciclovir.
    Sund F, Wahlberg J, Eriksson BM.
    J Clin Virol; 2001 Dec 13; 23(1-2):107-11. PubMed ID: 11595589
    [Abstract] [Full Text] [Related]

  • 4. Cytomegalovirus infection post-pancreas-kidney transplantation--results of antiviral prophylaxis in high-risk patients.
    Fallatah SM, Marquez MA, Bazerbachi F, Schiff JR, Cattral MS, McGilvray ID, Norgate A, Selzner M, Rotstein C, Husain S.
    Clin Transplant; 2013 Dec 13; 27(4):503-9. PubMed ID: 23731387
    [Abstract] [Full Text] [Related]

  • 5. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.
    Reischig T, Opatrny K, Bouda M, Treska V, Jindra P, Svecova M.
    Transpl Int; 2002 Dec 13; 15(12):615-22. PubMed ID: 12478408
    [Abstract] [Full Text] [Related]

  • 6. Low-dose valaciclovir prophylaxis against cytomegalovirus disease in renal transplant recipients.
    Reddy SP, Handa A, Tan L, Devaney A, Hughes D, Mason P, Friend PJ, Darby CR.
    Transpl Int; 2003 Oct 13; 16(10):726-9. PubMed ID: 12827230
    [Abstract] [Full Text] [Related]

  • 7. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection.
    Reischig T, Jindra P, Svecová M, Kormunda S, Opatrný K, Treska V.
    J Clin Virol; 2006 Jun 13; 36(2):146-51. PubMed ID: 16531113
    [Abstract] [Full Text] [Related]

  • 8. Adverse neuropsychiatric effects of cytomegalovirus prophylaxis with valaciclovir in renal transplant recipients.
    Das V, Peraldi MN, Legendre C.
    Nephrol Dial Transplant; 2006 May 13; 21(5):1395-401. PubMed ID: 16401626
    [Abstract] [Full Text] [Related]

  • 9. Prospective comparison of valacyclovir and oral ganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients.
    Reischig T, Opatrný K, Treska V, Mares J, Jindra P, Svecová M.
    Kidney Blood Press Res; 2005 May 13; 28(4):218-25. PubMed ID: 16043964
    [Abstract] [Full Text] [Related]

  • 10. A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients.
    Pavlopoulou ID, Syriopoulou VP, Chelioti H, Daikos GL, Stamatiades D, Kostakis A, Boletis JN.
    Clin Microbiol Infect; 2005 Sep 13; 11(9):736-43. PubMed ID: 16104989
    [Abstract] [Full Text] [Related]

  • 11. The economic value of valacyclovir prophylaxis in transplantation.
    Squifflet JP, Legendre C.
    J Infect Dis; 2002 Oct 15; 186 Suppl 1():S116-22. PubMed ID: 12353196
    [Abstract] [Full Text] [Related]

  • 12. [The significance of risk-adapted antiviral prophylaxis and modern virus diagnosis for organ survival after kidney transplantation].
    Fricke L, Steinhoff J, Hartwig-Weber I, Bein G.
    Dtsch Med Wochenschr; 1997 May 02; 122(18):565-71. PubMed ID: 9190308
    [Abstract] [Full Text] [Related]

  • 13. Effect of cytomegalovirus prophylaxis with acyclovir on renal transplant survival.
    Abraham KA, O'Kelly P, Spencer S, Hickey DP, Conlon PJ, Walshe JJ.
    Ren Fail; 2008 May 02; 30(2):141-6. PubMed ID: 18300112
    [Abstract] [Full Text] [Related]

  • 14. Pharmacoepidemiology of cytomegalovirus prophylaxis in a large retrospective cohort of kidney transplant recipients with Medicare Part D coverage.
    Santos CA, Brennan DC, Saeed MJ, Fraser VJ, Olsen MA.
    Clin Transplant; 2016 Apr 02; 30(4):435-44. PubMed ID: 26841129
    [Abstract] [Full Text] [Related]

  • 15. Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients.
    Reischig T, Nemcová J, Vanecek T, Jindra P, Hes O, Bouda M, Treska V.
    Antivir Ther; 2010 Apr 02; 15(1):23-30. PubMed ID: 20167988
    [Abstract] [Full Text] [Related]

  • 16. Pharmacoeconomic impact of different regimens to prevent cytomegalovirus infection in renal transplant recipients.
    Kielberger L, Bouda M, Jindra P, Reischig T.
    Kidney Blood Press Res; 2012 Apr 02; 35(6):407-16. PubMed ID: 22584353
    [Abstract] [Full Text] [Related]

  • 17. Long-term outcome of cytomegalovirus infection in simultaneous pancreas-kidney transplant recipients without ganciclovir prophylaxis.
    Rayes N, Seehofer D, Kahl A, Kokott S, Pratschke J, Frei U, Neuhaus P.
    Transpl Int; 2007 Nov 02; 20(11):974-81. PubMed ID: 17680782
    [Abstract] [Full Text] [Related]

  • 18. Low-dose valaciclovir and cytomegalovirus immunoglobulin to prevent cytomegalovirus disease in high-risk renal transplant recipients.
    Toussaint ND, Tan MB, Nicholls K, Walker RG, Cohney SJ.
    Nephrology (Carlton); 2011 Jan 02; 16(1):113-7. PubMed ID: 21175987
    [Abstract] [Full Text] [Related]

  • 19. Cytomegalovirus prophylaxis in pediatric kidney transplantation: the Dutch experience.
    Jongsma H, Bouts AH, Cornelissen EA, Beersma MF, Cransberg K.
    Pediatr Transplant; 2013 Sep 02; 17(6):510-7. PubMed ID: 23890076
    [Abstract] [Full Text] [Related]

  • 20. Prophylactic CMV therapy does not improve three-yr patient and graft survival compared to preemptive therapy.
    Werzowa J, Schwaiger B, Hecking M, Strassl R, Schmaldienst S, Böhmig GA, Genser B, Säemann MD.
    Clin Transplant; 2015 Dec 02; 29(12):1230-8. PubMed ID: 26458731
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.